GIP and diabetes mellitus: The glucagon‐like peptide 1 (GLP‐1) receptor agonists and the dual gastric inhibitory peptide (GIP)/GLP‐1 receptor agonist tirzepatide are indicated as second line treatments for type 2 diabetes mellitus and for weight management in obese (body mass index >30 kg.m−2) or overweight (body mass index >27 kg.m−2) patients with weight‐related comorbidities.1